Avidity Partners Management LP
In its 13F for Q2 2026 (holdings as of June 30, 2026, filed August 14, 2026), Avidity Partners Management LP reported 45 stock positions worth $624.4 million. Its top holding was Dianthus Therapeutics (DNTH) at 32.8% of the portfolio, followed by CG Oncology (CGON, 15.9%) and Oruka Therapeutics (ORKA, 11.6%). Compared with Q1 2026, it opened 13 new positions, sold out of 13, added to 11 and reduced 6. The biggest buy was Jade Biosciences (JBIO, shares +21%) and the biggest sale Teva Pharmaceutical-SP ADR (TEVA, shares −56%).
- Most Recent 13F
- Q2 2026
- Location
- DALLAS, TX
- CIK
- 0001791827
- Portfolio Value
- $624.4M (Q2 2026)
- SEC Filing
- 0001791827-26-000005 ↗ filed Aug 14, 2026
Holdings Value
Holdings 45 stocks · $624.4M
| DNTH Dianthus Therapeutics Inc. | 32.85% | 2,104,184 | $205.1M | No change |
| CGON CG Oncology Inc. | 15.92% | 1,398,948 | $99.4M | Add +8.5% |
| ORKA Oruka Therapeutics Inc. | 11.59% | 760,424 | $72.4M | No change |
| JBIO Jade Biosciences Inc. | 6.05% | 1,700,708 | $37.8M | Add +21.4% |
| ELVN Enliven Therapeutics Inc. | 4.47% | 550,000 | $27.9M | Add +37.5% |
| CATX Perspective Therapeutics Inc. | 3.44% | 6,299,999 | $21.5M | Add +4.1% |
| AKTS Aktis Oncology Inc. | 2.50% | 484,200 | $15.6M | Add +3.3% |
| PVLA Palvella Therapeutics Inc. | 1.71% | 70,000 | $10.7M | No change |
| MOBI Mobia Medical Inc. | 1.71% | 798,282 | $10.7M | New |
| RGEN Repligen Corp. | 1.70% | 77,800 | $10.6M | No change |
| IMUX Immunic Inc. | 1.65% | 669,941 | $10.3M | No change |
| SENS Senseonics Holdings Inc. | 1.46% | 1,600,000 | $9.1M | New |
| KPTI Karyopharm Therapeutics Inc. | 1.45% | 924,487 | $9.0M | Add +99.3% |
| TEVA Teva Pharmaceutical-SP ADR | 1.09% | 200,000 | $6.8M | Reduce -55.6% |
| DXCM Dexcom Inc. | 1.08% | 100,000 | $6.7M | Add +11.1% |
| TEM Tempus AI Inc. Class A | 0.97% | 105,000 | $6.1M | Add +320.0% |
| MDT Medtronic PLC | 0.88% | 70,000 | $5.5M | Reduce -30.0% |
| VIR Vir Biotechnology Inc. | 0.85% | 519,300 | $5.3M | Reduce -45.3% |
| GPCR Structure Therapeutics Inc. | 0.84% | 98,000 | $5.3M | Add +226.7% |
| EHC Encompass Health Corp. | 0.68% | 42,000 | $4.2M | No change |
| TENX Tenax Therapeutics Inc. | 0.62% | 265,934 | $3.9M | Add +23.2% |
| NVCT Nuvectis Pharma Inc. | 0.59% | 200,000 | $3.7M | New |
| PODD Insulet Corp. | 0.59% | 24,000 | $3.7M | New |
| BSX Boston Scientific Corp. | 0.55% | 80,000 | $3.4M | Add +33.3% |
| MSLE Satellos Bioscience Inc. | 0.48% | 387,769 | $3.0M | No change |
| ALMR Alamar Biosciences Inc. | 0.48% | 110,000 | $3.0M | New |
| CNTX Context Therapeutics Inc. | 0.44% | 4,998,267 | $2.8M | No change |
| GILD Gilead Sciences Inc. | 0.40% | 20,000 | $2.5M | No change |
| CRL Charles River Laboratories | 0.36% | 10,000 | $2.3M | New |
| PHAT Phathom Pharmaceuticals Inc. | 0.35% | 200,000 | $2.2M | Reduce -19.8% |
| AVLN Avalyn Pharma Inc. | 0.32% | 60,000 | $2.0M | New |
| KLRA Kailera Therapeutics Inc. | 0.28% | 80,000 | $1.8M | New |
| GMAB Genmab A/S -SP ADR | 0.22% | 50,000 | $1.4M | No change |
| NTLA Intellia Therapeutics Inc. | 0.20% | 75,000 | $1.3M | No change |
| CRVS Corvus Pharmaceuticals Inc. | 0.19% | 80,000 | $1.2M | Reduce -30.4% |
| ODD Oddity Tech Ltd. Class A | 0.17% | 70,000 | $1.1M | No change |
| SCYX Scynexis Inc. | 0.17% | 260,206 | $1.1M | No change |
| EVMN Evommune Inc. | 0.16% | 75,000 | $997K | New |
| ABT Abbott Laboratories | 0.15% | 10,000 | $907K | New |
| BBIO Bridgebio Pharma Inc. | 0.12% | 10,000 | $745K | New |
| PTON Peloton Interactive Inc. Class A | 0.09% | 100,000 | $591K | Reduce -50.0% |
| LEGN Legend Biotech Corp.-ADR | 0.07% | 15,000 | $433K | New |
| BBOT Bridgebio Oncology Therapeut | 0.05% | 43,853 | $334K | No change |
| SVRA Savara Inc. | 0.05% | 50,000 | $308K | New |
| TRVI Trevi Therapeutics Inc. | 0.02% | 6,660 | $124K | No change |
Portfolio Sells Q1 2026 → Q2 2026
| TEVA Teva Pharmaceutical-SP ADR | Reduce -55.6% | 1.09% | −1.66 |
| MDT Medtronic PLC | Reduce -30.0% | 0.88% | −0.88 |
| VIR Vir Biotechnology Inc. | Reduce -45.3% | 0.85% | −0.88 |
| CNC Centene Corp. | Sold out | 0.00% | −0.46 |
| NTRA Natera Inc. | Sold out | 0.00% | −0.36 |
| ICLR Icon PLC | Sold out | 0.00% | −0.36 |
| KVUE Kenvue Inc. | Sold out | 0.00% | −0.35 |
| HIMS Hims & Hers Health Inc. | Sold out | 0.00% | −0.32 |
| RVMD Revolution Medicines Inc. | Sold out | 0.00% | −0.30 |
| CORT Corcept Therapeutics Inc. | Sold out | 0.00% | −0.24 |
| ABVX Abivax SA-ADR | Sold out | 0.00% | −0.23 |
| PHAT Phathom Pharmaceuticals Inc. | Reduce -19.8% | 0.35% | −0.21 |
| UNH Unitedhealth Group Inc. | Sold out | 0.00% | −0.21 |
| MLTX Moonlake Immunotherapeutics | Sold out | 0.00% | −0.19 |
| AVR Anteris Technologies Global | Sold out | 0.00% | −0.17 |
| CRVS Corvus Pharmaceuticals Inc. | Reduce -30.4% | 0.19% | −0.15 |
| ABUS Arbutus Biopharma Corp. | Sold out | 0.00% | −0.11 |
| PTON Peloton Interactive Inc. Class A | Reduce -50.0% | 0.09% | −0.08 |
| ACAD Acadia Pharmaceuticals Inc. | Sold out | 0.00% | −0.06 |
Portfolio Buys Q1 2026 → Q2 2026
| JBIO Jade Biosciences Inc. | Add +21.4% | 6.05% | +2.07 |
| MOBI Mobia Medical Inc. | New | 1.71% | +1.71 |
| SENS Senseonics Holdings Inc. | New | 1.46% | +1.46 |
| ELVN Enliven Therapeutics Inc. | Add +37.5% | 4.47% | +1.29 |
| KPTI Karyopharm Therapeutics Inc. | Add +99.3% | 1.45% | +0.92 |
| AKTS Aktis Oncology Inc. | Add +3.3% | 2.50% | +0.80 |
| TEM Tempus AI Inc. Class A | Add +320.0% | 0.97% | +0.75 |
| NVCT Nuvectis Pharma Inc. | New | 0.59% | +0.59 |
| PODD Insulet Corp. | New | 0.59% | +0.59 |
| GPCR Structure Therapeutics Inc. | Add +226.7% | 0.84% | +0.55 |
| ALMR Alamar Biosciences Inc. | New | 0.48% | +0.48 |
| CRL Charles River Laboratories | New | 0.36% | +0.36 |
| AVLN Avalyn Pharma Inc. | New | 0.32% | +0.32 |
| KLRA Kailera Therapeutics Inc. | New | 0.28% | +0.28 |
| EVMN Evommune Inc. | New | 0.16% | +0.16 |
| ABT Abbott Laboratories | New | 0.15% | +0.15 |
| BBIO Bridgebio Pharma Inc. | New | 0.12% | +0.12 |
| LEGN Legend Biotech Corp.-ADR | New | 0.07% | +0.07 |
| SVRA Savara Inc. | New | 0.05% | +0.05 |
| DXCM Dexcom Inc. | Add +11.1% | 1.08% | −0.07 |
| TENX Tenax Therapeutics Inc. | Add +23.2% | 0.62% | −0.08 |
| BSX Boston Scientific Corp. | Add +33.3% | 0.55% | −0.22 |
| CATX Perspective Therapeutics Inc. | Add +4.1% | 3.44% | −1.67 |
| CGON CG Oncology Inc. | Add +8.5% | 15.92% | −1.75 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 45 | $624.4M | DNTH, CGON, ORKA, JBIO, ELVN |
| Q1 2026Amended | 45 | $493.8M | DNTH, CGON, ORKA, CATX, JBIO |
| Q4 2025 | 39 | $346.7M | DNTH, CGON, JBIO, ORKA, TEVA |
| Q3 2025 | 43 | $439.4M | DNTH, CGON, MDT, BSX, ORKA |
| Q2 2025 | 55 | $498.8M | CGON, BSX, NTRA, DNTH, EXAS |
| Q1 2025 | 63 | $484.9M | BSX, DNTH, UNH, CGON, HUM |
| Q4 2024 | 61 | $1.0B | DNTH, BSX, JANX, NTRA, EXAS |
| Q3 2024 | 81 | $2.0B | BSX, DNTH, ISRG, NTRA, CGON |
| Q2 2024 | 84 | $2.4B | ISRG, BSX, NTRA, ARVN, ACHC |
| Q1 2024 | 86 | $2.8B | FUSN, BSX, ARVN, ISRG, DNTH |